Clinical trials: Cancer, Head
Esophageal Squamous Cell Carcinoma
Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma
This is a prospective single-arm study of endoscopic resection (ER) following concurrent chemoradiotherapy for stage I esophageal squamous cell carcinoma, to find if the treatment combination is useful by assessing its safety and…
- Trial name
- NCT04275986
- Testing
- Intensity modulated radiotherapy (IMRT), Chemotherapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Chinese Academy of Medical Sciences
HNSCC, Head and Neck Neoplasms
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Phase II study of Durvalumab+/- Tremelimumab in patients with recurred metastatic head and neck squamous cell carcinoma
- Trial name
- NCT06446570
- Testing
- Durvalumab,Tremelimumab
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Seoul National University Hospital
Cancer Head Neck, Cancer, Head
Randomized Evaluation of Machine Learning Assisted Radiation Treatment Planning vs Standard Radiation Treatment Planning
The purpose of this study is to determine the magnitude of clinical benefit achieved through machine learning assisted radiation treatment planning (MLAP) on post-treatment clinical outcomes such as acute toxicity and patient…
- Conditions
- Cancer Head Neck, Cancer, Head, Cancer Neck
- Trial name
- NCT05979883
- Testing
- Machine Learning Assisted Radiation (MLAP) RapidPlan, Radiation Therapy Standard of Care (SOC)
- Where
- 6 sites in United States
- Volunteers
- 204 people
- Sponsor
- Mayo Clinic
Esophageal Squamous Cell Carcinoma
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
To evaluate the efficacy and safety of paclitaxel and DDP combined with Anlotinib in the treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT04063683
- Testing
- Anlotinib Hydrochloride, Paclitaxel, cisplatin
- Where
- 6 sites in China
- Volunteers
- 47 people
- Sponsor
- Henan Cancer Hospital
Head and Neck Cancer Squamous Cell
Reirradiation and Erbitux in the HNSCC
The purpose of this study is to investigate in patients with cancer of the throat and recurrent inoperable a different modality treatment consisting of radiation continuously for 5 weeks and half associated with a drug directed…
- Trial name
- NCT01237483
- Testing
- Erbitux
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
The purpose of the study is to assess the role of lymphoscintigraphy as a simple and widely accessible method with a favorable cost/benefit ratio in improving oral cavity and oropharyngeal squamous cell carcinoma staging and…
- Trial name
- NCT03727594
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University Hospital of Ferrara
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
This study aims to compare the efficacy and safety of short-course definitive concurrent chemoradiotherapy plus immunotherapy followed by immunotherapy maintenance versus short-course definitive chemoradiotherapy plus…
- Trial name
- STELLAR01 (NCT07530094)
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Ning Jiang, M.D./Ph.D.
Esophageal Cancer, Gastric Cancer
Nutrition Intervention Trials in Linxian Follow-up Study
Two large, nutritional intervention trials were conducted in Linxian, China between 1985-1991. These trials tested the effect of multiple vitamins and minerals in the prevention of esophageal cancer in a population with the…
- Trial name
- NCT00342654
- Where
- China
- Volunteers
- 32,902 people
- Sponsor
- National Cancer Institute (NCI)
Siewert Type II Adenocarcinoma of Esophagogastric Junction
Siewert Type II Esophageal Adenocarcinoma: Relationship Between Histology and Survival
In Siewert type II adenocarcinoma, the relationship between adenocarcinoma sub types and survival, histologic/biologic patterns related to the presence/absence of gastric greater curvature metastases, were investigated.
- Trial name
- SiewertIIEAC (NCT03416101)
- Testing
- Total Gastrectomy
- Where
- 2 sites in Italy
- Volunteers
- 154 people
- Sponsor
- University of Bologna
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Nasopharyngeal Carcinoma, Endoscopic Surgery
Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
Nasopharyngeal carcinoma (NPC) is most prevalent in eastern Asia, with the highest incidence reported among the Cantonese population from the province of Guangdong.
- Conditions
- Nasopharyngeal Carcinoma, Endoscopic Surgery, Primary Napharyngeal Carcinama, Stage I Nasopharyngeal Cancer
- Trial name
- NCT03353467
- Testing
- Endoscopic surgery, Intensity-modulated radiotherapy
- Where
- 5 sites in China
- Volunteers
- 228 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Comparison of patients with operable, recurrent previously-irradiated squamous cell head-and-neck cancers with or without adjuvant SBRT.
- Trial name
- NCT02516969
- Testing
- Stereotactic Body Radiotherapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- David A. Clump, MD, PhD
Gastrointestinal Tumors, Colorectal Adenocarcinomas
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
- Conditions
- Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
- Trial name
- NCT04171141
- Testing
- PF-07062119, Anti-PD1, Anti-VEGF
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Squamous Cell Carcinoma of the Head and Neck
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT05459129
- Testing
- Atezolizumab, Tiragolumab, Carboplatin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer
Tissue Collection Protocol for Gastroesophageal Cancers
This proposed collection of primary tumor cells lines will benefit esophageal cancer research within the University Health Network.
- Trial name
- NCT02495337
- Testing
- Tissue Collection
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Cervical Cancer, Colorectal Cancer
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- STARBURST (NCT05563272)
- Testing
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Hyperparathyroidism, Hypercalcemia
Studies of Elevated Parathyroid Activity
Observational Phase: Patients whose parathyroid activity is elevated above normal are referred to as having hyperparathyroidism.
- Conditions
- Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia
- Trial name
- NCT00001277
- Testing
- 68Ga-Dotatate, 18F-DOPA
- Where
- United States
- Volunteers
- 1,553 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Drug Use for Unapproved Schedule
EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug
PCR-DNA of EBV test is a good prognostic indicator for survival after treatment (report: Prognostic Impact of Plasma, Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation…
- Trial name
- NCT03656965
- Testing
- Acyclovir 800 MG, Radiotherapy and chemotherapy
- Where
- Kuwait
- Volunteers
- 50 people
- Sponsor
- Kuwait Cancer Control Center
Esophageal Carcinoma, Neoadjuvant Therapy
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
The purpose of this study is to explore the effectiveness and safety of the combination of Anlotinib, Toripalimab, and albumin-bound paclitaxel with cisplatin for neoadjuvant therapy in resectable esophageal squamous cell…
- Trial name
- NCT05996484
- Testing
- Toripalimab, Anlotinib hydrochloride, Albumin paclitaxel
- Volunteers
- 25 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Carcinoma
Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma
anlotinib was added to TP inductive chemotherapy and definitive chemoradiation in nasopharyngeal carcinoma patients with N2-3 disease with necrosis or/and ECM
- Trial name
- NCT05232552
- Testing
- Anlotinib hydrochloride, induction chemotherapy, concurrent chemoradiation
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Zhejiang Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.